News

In vivo Proof-of-Concept of AX-202 presented at EULAR 2021 by Dr. Michal Tomčík

Anti-S100A4 monoclonal antibody treatment ameliorates skin fibrosis in inflammatory and noninflammatory pre-clinical models of systemic sclerosis

Arxx Therapeutics Secures NOK110 Million in Seed Round

Funding to support clinical phase 1 readiness

Get in touch

    We are dedicated to developing transformative therapies for patients with fibrotic disease.
    We believe that AX-202 has the potential to transform how fibrosis is treated and help many patients poorly served by current therapeutic options.
    Arxx Therapeutics
    in Norway: Gaustadalléen 21, 0349 Oslo
    in Denmark: Symbion Science Park, Fruebjergvej 3, 2100 Copenhagen 
    © 2021 Arxx Therapeutics. All rights reserved. | Privacy Policy